Chen Yu jumps ship from Vivo Capital and goes large, allying with The Column Group on an inaugural $824M biotech crossover fund
Over the past 15 years, the crew at The Column Group have gathered more than $2 billion together to pursue their game plan of fostering biotech startups. And it’s been effective. Their portfolio plays have provided a target-rich environment for big players like Roche and J&J and Vertex to come stalking acquisitions.
Recently, though, one of the managing partners at Vivo Capital jumped ship after a very long tenure — 17 years — and went on to quickly create a brand new biotech fund they’re partnered with the VC on called TCG Crossover; TCG X in abbreviated fashion. His name is Chen Yu, and in the midst of the busiest crossover season in the industry’s history, he’s jumping in to the game with an $824 million stake that will be put into play at the junction intersecting biotechs with public markets — with a special side focus on the booming China market, where he’s been a player for years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.